Anticoagulant Reversal Drugs Market Size (2024 - 2029)

The anticoagulant reversal drugs market is poised for significant expansion, driven by an increase in cardiovascular conditions, atrial fibrillation, and a growing geriatric population. The market's growth trajectory was notably influenced by the COVID-19 pandemic, which accelerated research and usage due to complications like abnormal blood clotting in infected patients. As the market stabilizes to pre-pandemic levels, the demand is expected to rise, although potential side effects of the drugs may pose challenges.

Market Size of Anticoagulant Reversal Drugs Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Anticoagulant Reversal Drugs Market  Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
CAGR 12.01 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Anticoagulant Reversal Drugs Market  Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Anticoagulant Reversal Drugs Market Analysis

The anticoagulant reversal drugs market is expected to witness a CAGR of 12.01% over the forecast period.

COVID-19 significantly impacted the anticoagulant reversal drugs market owing to the increasing pace of research activities on COVID-19 infection. For instance, per the data from the American Journal of Cardiovascular Drugs, in 2020, more than 10 clinical trials were in progress to evaluate the potential of factor Xa inhibitors in COVID-19 patients, and research on strategies for the parenteral administration of these drugs was worked upon to be used in critically ill COVID-19 patients. Additionally, it was observed that several patients with COVID-19 had developed abnormal blood clotting, which increased the use of anticoagulants during the pandemic. Therefore, the COVID-19 pandemic had a significant impact on the market studied. However, the market is currently reaching its pre-pandemic nature and is expected to witness healthy growth in the coming years.

The major factors driving the market are a rise in the global prevalence of multiple cardiovascular indications, atrial fibrillation, an increase in intracranial and gastrointestinal hemorrhages, and the increasing geriatric population. As per the 2021 data from the CDC, every year, 805,000 people in the United States have a heart attack, 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. Similarly, as stated by the American Heart Association 2021 journal, it is estimated that by the year 2035, more than 130 million adults in the United States will have some type of heart disease. The increasing burden of cardiovascular diseases in major countries such as the United States is believed to propel market growth over the forecast period.

Additionally, the increasing burden of blood diseases is augmenting the demand for anticoagulant reversal drugs. For instance, as per the National Family Health Surveys (NFHS) conducted in 2021, the prevalence of anemia in Indian adults was around 59% in women and 31% in men in 2021. With this development, there will be market growth in the coming years.

However, the side effects associated with the drug may restrain the market during the forecast period.

Anticoagulant Reversal Drugs Industry Segmentation

Anticoagulant reversal drugs are prescribed medications that are used to reverse or balance bleeding and thrombotic risks for individuals with an overdose of anticoagulant therapy or when unplanned surgery is required. The Anticoagulant Reversal Drugs Market is Segmented by Drug Class (Prothrombin Complex Concentrates, Coagulation Factors, Monoclonal Antibodies, Phytonadione, and Other Drug Classes), End User (Hospital Pharmacies, Retail Pharmacies, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Prothrombin Complex Concentrates
Coagulation Factors
Monoclonal Antibodies
Phytonadione
Other Drug Classes
By End User
Hospital Pharmacies
Retail Pharmacies
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Anticoagulant Reversal Drugs Market Size Summary

The anticoagulant reversal drugs market is poised for substantial growth, driven by the increasing prevalence of cardiovascular conditions and the aging population. The market experienced a significant impact due to the COVID-19 pandemic, which heightened the demand for anticoagulants as many patients developed abnormal blood clotting. This led to a surge in research activities focused on the use of factor Xa inhibitors in COVID-19 patients. As the market stabilizes post-pandemic, it is expected to regain its momentum, supported by the rising incidence of atrial fibrillation, intracranial and gastrointestinal hemorrhages, and the growing burden of blood diseases. The development and approval of new drugs, such as Andexxa, have also contributed to the market's expansion, with companies increasingly investing in research and development to meet the evolving needs of patients.

North America is anticipated to lead the anticoagulant reversal drugs market throughout the forecast period, bolstered by its advanced healthcare infrastructure and direct reimbursement policies. The United States, in particular, holds a significant market share due to the high prevalence of cardiovascular diseases and the expedited drug approval processes by the FDA. The region's market growth is further supported by awareness programs and prevention initiatives by organizations like the CDC. Key players in the market, including Pfizer Inc., Boehringer Ingelheim GmbH, and Portola Pharmaceuticals Inc., are actively engaging in strategic acquisitions and product launches to strengthen their market positions. The market's consolidation and the ongoing development of new anticoagulant products are expected to drive robust growth in the coming years.

Explore More

Anticoagulant Reversal Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Geriatric Population and Growing Blood Disorders

      2. 1.2.2 New Product Launches due to Accelerated Drug Approval Initiative by USFDA

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects Associated with the Drugs

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size - Value in USD million)

    1. 2.1 By Drug Class

      1. 2.1.1 Prothrombin Complex Concentrates

      2. 2.1.2 Coagulation Factors

      3. 2.1.3 Monoclonal Antibodies

      4. 2.1.4 Phytonadione

      5. 2.1.5 Other Drug Classes

    2. 2.2 By End User

      1. 2.2.1 Hospital Pharmacies

      2. 2.2.2 Retail Pharmacies

      3. 2.2.3 Other End Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Anticoagulant Reversal Drugs Market Size FAQs

The Anticoagulant Reversal Drugs Market is projected to register a CAGR of 12.01% during the forecast period (2024-2029)

Portola Pharmaceuticals Inc, Pfizer Inc, Octapharma AG, CSL Behring Limited and Boehringer Ingelheim Pharma GmbH are the major companies operating in the Anticoagulant Reversal Drugs Market.

Anticoagulant Reversal Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)